See also this year's filing and all EDGAR filings for this company.
PDF Report 0001593899_2023_Atea_Pharmaceuticals_Inc.pdf
Logs
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'OperatingExpenses', 'revenue_node': 'RevenueFromContractWithCustomerExcludingAssessedTax', 'net_inc_node': 'NetIncomeLoss'} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.3833936722808122, 'aggregate_val': 175774000, 'exp_sum': 127060000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 48714000, 'ResearchAndDevelopmentExpense': 81936000, 'remainder_Expenses': -3590000}} |
Graph
Absolute values for 0001593899, Atea Pharmaceuticals Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 660,922,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 1,705,000 |
| 3 | remainder_Assets | 4,081,000 |
| 4 | LiabilitiesCurrent | 18,478,000 |
| 5 | LiabilitiesNoncurrent | 2,403,000 |
| 6 | remainder_Liabilities | 5,255,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 48,714,000 |
| 9 | ResearchAndDevelopmentExpense | 81,936,000 |
| 10 | remainder_Expenses | 45,124,000 |
| 11 | remainder_Revenues | 11,151,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | -684,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 666,708,000 |
| 1 | Liabilities | 26,136,000 |
| 2 | Expenses | 175,774,000 |
| 3 | Revenues | 11,151,000 |
| 4 | StockholdersEquity | 640,572,000 |
| 5 | NetIncome | -164,623,000 |
| 6 | ComprehensiveNetIncome | -164,965,000 |
| 7 | BaseVar | 440,226,500 |
| 8 | EconomicCapitalRatio | 2.70 |
Edgar->Model Mapping
Feature Distribution
Change over Time
